Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram
Open Access
- 23 April 2019
- journal article
- research article
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 25 (1) , 50-63
Abstract
Objective: The objective of this work was to describe treatment-emergent sexual dysfunction (TESD) and tolerability following a switch from selective serotonin reuptake inhibitor (SSRI: citalopram, paroxetine, or sertraline) monotherapy to vortioxetine or escitalopram monotherapy in adults with well-treated major depressive disorder (MDD) and SSRI-induced sexual dysfunction.Methods: Data were analyzed from the primary study, an 8-week, randomized, double-blind, head-to-head study in which participants with well-treated depressive symptoms but experiencing TESD with SSRIs were directly switched to flexible doses (10/20 mg) of vortioxetine or escitalopram. Sexual functioning was assessed by the Changes in Sexual Functioning Questionnaire-14 (CSFQ-14), efficacy by the Montgomery–Åsberg Depression Rating Scale scores (MADRS) and Clinicians Global Impression of Severity/Improvement (CGI-S/CGI-I), and tolerability by adverse events. Efficacy and tolerability were assessed by pre-switch SSRI therapy where possible, and by participant characteristics.Results: Greater improvements in TESD were seen in the vortioxetine compared with escitalopram groups based on: participant demographics (≤45 years, women; P = 0.045), prior SSRI treatment (P = 0.044), number of prior major depressive episodes (MDEs) (1–3; P = 0.001), and duration of prior SSRI therapy (>1 year; P = 0.001). Prior SSRI treatment did not appear to influence the incidence or severity of TEAEs, except for nausea. Regardless of prior SSRI, both treatments maintained antidepressant efficacy after 8 weeks.Conclusion: Results suggest that vortioxetine is a safe and effective switch therapy for treating SSRI-induced sexual dysfunction in adults with well-treated MDD. Also, improvement in sexual dysfunction with vortioxetine or escitalopram may be influenced by prior SSRI usage, sex, age, and history of MDEs.Keywords
This publication has 29 references indexed in Scilit:
- Sexual Functioning in Patients With Recurrent Major Depressive Disorder Enrolled in the PREVENT StudyJournal of Nervous & Mental Disease, 2013
- A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder*International Journal of Neuropsychopharmacology, 2012
- Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational studyInternational Journal of Psychiatry in Clinical Practice, 2011
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- Treatment-Emergent Sexual Dysfunction Related to AntidepressantsJournal of Clinical Psychopharmacology, 2009
- Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient surveyJournal of Psychopharmacology, 2009
- Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive DisorderThe Journal of Clinical Psychiatry, 2009
- Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive DisorderThe Journal of Sexual Medicine, 2007
- Estimating the Prevalence and Impact of Antidepressant-Induced Sexual Dysfunction in 2 European CountriesThe Journal of Clinical Psychiatry, 2006
- Accommodation to serotonin reuptake inhibitor-induced sexual dysfunitionJournal of Sex & Marital Therapy, 1998